ADAPT-C Sub-Study: Community-based cohort of people tested for COVID-19

Participation will involve a maximum of 4 study visits to the Clinic over a 12 month period. 3x Negative Control Cohorts will be recruited Cohort C (n=50): COVID-19 negative, other coronavirus positive Cohort D (n=50-100): COVID-19 negative, respiratory viral panel negative, no known epidemiological risk factor for COVID-19 infection Cohort E (n=50): COVID-19 negative, respiratory viral panel negative, known epidemiological risk factor for COVID-19 infection (close contact of known COVID-19 case, overseas travel in 2 weeks prior to testing date) Participation will include Blood sampling 27mLs blood collected in SST and EDTA tubes (and an optional 36mLs in ACD tubes) will be taken at each time point in the study to create a biobank of samples suitable for COVID-19 related immunovirological research, and serological assay evaluation. Dried blood spot sampling A dried blood spot (DBS) will be collected at each time point (in comparison to phlebotomy sampling). DBS can be self-collected by participants at home if required. DBS will be mailed to participant with instructions on self-completion using standard educational materials developed for the use of DBS in HIV and HCV research. Health-Related Quality of Life (HRQoL) measures Study subjects will be asked to complete standardized HRQoL questionnaires at pre-specified follow-up timepoints. Survey instruments have been selected for general health measures, response to a major event and for psychological outcomes as follows: • Depression Scale • Impact of Events Scale • Somatic and Psychological Health Report (SPHERE) • EQ-5D Functional Impact of Illness